Home > Dermatology > EADV 2019 > Late-Breaking News > Green light for a second JAK inhibitor in AD

Green light for a second JAK inhibitor in AD

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Conference
EADV 2019
Trial
Phase 3, JADE MONO-1
Monotherapy with the Janus kinase (JAK) inhibitor abrocitinib demonstrated remarkable efficacy: significant differences in skin clearance compared with placebo could be shown as early as 2 weeks in the phase 3 JADE MONO-1 trial [1]. After positive results in phase 2 trials [2], the 100 mg and 200 mg doses of abrocitinib were assessed in a phase 3 trial. Adolescents (> 12 years) and adults with moderate-to-severe atopic dermatitis (AD) were included and treated with the 2 dosages or placebo. The co-primary endpoints in JADE MONO-1 were achievement of an Investigator Global Assessment (IGA) score of 0 or 1 at week 12 and an EASI 75 response. “With a mean EASI score of about 30 at baseline, we treated a population quite impacted by the disease,” said Prof. Eric Simpson (Oregon Health & Science University, USA). A clear-cut dose response was evident in th...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on